|
Nov 12, 2019
|
Sesen Bio Reports Third Quarter 2019 Financial Results and Update on Regulatory Activities Related to Vicinium
On Track for Anticipated Initiation of BLA Submission in December, 2019 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 12, 2019-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported financial
|
|
Nov 5, 2019
|
Sesen Bio Announces Successful Type C Meeting with FDA for Vicinium
Alignment reached with FDA on post-marketing confirmatory trial design CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2019-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported alignment with
|
|
Oct 29, 2019
|
Sesen Bio Strengthens Strategic and Financial Optionality
Company to Host Conference Call to Provide Business Update on November 12, 2019 at 8 a.m. EST CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 29, 2019-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today
|
|
Sep 3, 2019
|
Sesen Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2019-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the H.C.
|
|
Aug 26, 2019
|
Sesen Bio Announces CFO Transition as Company Drives Towards Anticipated Initiation of BLA Submission in 4Q 2019
Company Appoints Monica Forbes as Chief Financial Officer and Kirstin Anderson as Principal Accounting Officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 26, 2019-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients
|
|
Aug 8, 2019
|
Sesen Bio Reports Positive, Preliminary Data Update from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer
Updated 12-month Phase 3 Data will Serve as the Basis for Submission of the BLA On Track for Anticipated Initiation of BLA Submission in 4Q 2019 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2019-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics
|
|
Aug 5, 2019
|
Sesen Bio Strengthens Leadership Team
Company Appoints Seasoned Biotech Leaders to Oversee Legal, Corporate Strategy, Financial Planning, and Business Development and Alliance Management CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2019-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein
|
|
Jul 31, 2019
|
Sesen Bio to Present at the Canaccord Genuity 39th Annual Growth Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 31, 2019-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity 39th Annual
|
|
Jul 17, 2019
|
Sesen Bio Announces Retirement of Leslie L. Dan
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 17, 2019-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Leslie L. Dan has retired from the Company's Board of Directors, effective
|
|
Jun 19, 2019
|
Sesen Bio Announces Pricing of Public Offering of Common Stock and Warrants
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 19, 2019-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 20,410,000 shares of its common
|
